ASTEC

Astec LifeSciences Ltd.

Date: 29th October, 2025

To,
BSE Limited
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

Ref.: BSE Scrip Code No. “533138”

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai – 400 051

Ref.: “ASTEC”

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08023

<u>Sub.: Press Release</u>

The Board of Directors of Astec LifeSciences Limited (“the Company”), at its Meeting held on Wednesday, 29th October, 2025, has approved the Unaudited Financial Results (both Standalone and Consolidated) for the Quarter and Half Year ended 30th September, 2025.

We enclose a copy of the Press Release and the same is being placed on the website of the Company.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree
Rohan Pradhan

Digitally signed by Tejashree Rohan Pradhan
DN: c=IN, o=Personal, title=1500, pseudonym=6772abaea05446e9af7db0d1485a0332, 2.5.4.20=7e85e7813cc0727379015ad6d28a3b65295c6375608d78aea1ca152cafefaf7f, postalCode=400606, st=Maharashtra, serialNumber=cc444393f2150dc819f3d8164db345c555b40cb184b6ae8611cda7b9d64587a7, cn=Tejashree Rohan Pradhan
Date: 2025.10.29 18:15:33 +05'30'

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)

Encl.: As Above

ISO 9001:2015 ISO 14001:2015 OHSAS 45001/2018 Responsible Care®

Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236

ASTEC LIFESCIENCES LIMITED

"Godrej One", 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India

CIN: L99999MH1994PLC076236

PRESS RELEASE

Mumbai, 29th October, 2025: Astec LifeSciences Limited ("Astec") has today announced its financial results for the second quarter & Half Year ended September 30, 2025.

FINANCIAL OVERVIEW

Q2 FY26 Financial Summary

- *The Company reported consolidated total income of Rs. 74.8 crore in Q2FY26 as compared to Rs. 100.5 crore in Q2FY25.*
- *The Company reported consolidated EBITDA loss of Rs. 5.6 crore in Q2FY26 as compared to EBITDA loss of Rs. 17.7 crore in Q2 FY25.*

H1 FY26 Financial Summary

- *The Company reported consolidated total income of Rs. 166.4 crore in H1 FY26 as compared to Rs. 170.8 crore in H1 FY25.*
- *The Company reported consolidated EBITDA loss of Rs. 16.1 crore in H1 FY26 as compared to loss of Rs. 63.1 crore in H1 FY25.*

HIGHLIGHTS OF CONSOLIDATED FINANCIAL PERFORMANCE (Q2FY26 and H1 FY26)

(in Rs. crore)

Particulars	Q2FY26	Q2FY25	% Change	H1 FY26	H1 FY25	% Change
Total Income	74.8	100.5	-25.6%	166.4	170.8	-2.6%
Earnings before depreciation, interest and taxes (EBITDA)	(5.6)	(17.7)	NM	(16.1)	(63.1)	NM
Profit Before Tax (PBT)	(24.4)	(38.6)	NM	(57.4)	(100.2)	NM
Profit after Tax (PAT)	(24.4)	(38.6)	NM	(57.4)	(78.3)	NM

NM: Not Measurable

CHAIRMAN'S COMMENTS

Commenting on the performance, Mr. N B Godrej, Chairman, Astec LifeSciences Limited, said:

Astec recorded year-on-year and sequential improvement in its performance in Q2 FY26. The EBITDA loss narrowed to ₹ 5.6 crore, reflecting a positive trend compared to previous quarters. This improvement was largely driven by higher volumes and better gross margins in the Enterprise business. Conversely, the contract manufacturing segment experienced a year-on-year revenue decline, as the cautious stance adopted by the contract manufacturing customers impacted performance during the quarter.

Revenue from Operations (in Rs. crore)	**Q2FY26**	**Q2FY25**	**% Change**	**H1 FY26**	**H1 FY25**	**% Change**
Category Breakdown						
Enterprise	60.6	52.3	15.1%	96.6	74.1	30.4%
Contract Manufacturing & New Products	13.1	46.2	-71.6%	67.7	75.5	-10.3%
Other trading Sales	-	-	-	-	18.3	NM
Geography Breakdown						
Exports	41.1	63.4	-35.2%	87.0	94.5	-7.9%
Domestic	32.6	35.1	-7.2%	77.8	73.4	5.9%

- ENDS –

About Astec LifeSciences Limited

Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to over 18 countries including the United States and countries across Europe, West Asia, South-East Asia and Latin America and Africa.

For more information on the Company, please log on to www.godrejastec.com

For further information, please contact:

S. Varadaraj
Godrej Agrovet Limited
Email: s.varadaraj@godrejagrovet.com
Tel No.: +91 22 2519 4864

Mugdha Khare
Astec LifeSciences Limited
Email:mugdha.khare@godrejastec.com
Tel No.: +91 22 2519 5777

Amit Pendse
Godrej Agrovet Limited
Email: amit.pendse@godrejagrovet.com
Tel No.: +91 22 2519 4488